Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 401–500 of 1,001
How I treat HER2-low advanced breast cancer
Schlam, I. M., Tolaney, S. M., & Tarantino, P. (2023) · The Breast · doi:10.1016/j.breast.2023.01.005 · Cited by 48
Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
Wolfson, E., Solomon, S., Schmukler, E., Goldshmit, Y., & Pinkas‐Kramarski, R. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0067-7 · Cited by 45
Ivanova, E., Kuraguchi, M., Xu, M., Portell, A. J., Taus, L., Diala, I., Lalani, A. S., Choi, J., Chambers, E. S., Li, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1844 · Cited by 43
Wang, Z., Cheng, Y., Chen, S., Shao, H., Chen, X., Wang, Z., Wang, Y., Zhou, H., Chen, T., Lin, N., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.37 · Cited by 46
Breast cancer management in 2021: A primer for the obstetrics and gynecology
Fleege, N. M. G., & Cobain, E. F. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2022.02.004 · Cited by 52
Keith, K., Lee, Y. Z., Ewend, M. G., Zagar, T. M., & Anders, C. K. (2016) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2016.03.005 · Cited by 44
Polyglutamic Acid-Gated Mesoporous Silica Nanoparticles for Enzyme-Controlled Drug Delivery
Tukappa, A., Ultimo, A., de la Torre, C., Pardo, T., Sancenón, F., & Martínez‐Máñez, R. (2016) · Langmuir · doi:10.1021/acs.langmuir.6b01715 · Cited by 44
Beitsch, P. D., Whitworth, P. W., Baron, P. L., Rotkis, M. C., Mislowsky, A. M., Richards, P. D., Murray, M. K., Pellicane, J. V., Dul, C. L., Nash, C. H., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5863-x · Cited by 44
The importance of greater speed in drug development for advanced malignancies
Stewart, D. J., Stewart, A. A., Wheatley‐Price, P., Batist, G., Kantarjian, H. M., Schiller, J. H., Clemons, M. J., Bradford, J., Gillespie, L., & Kurzrock, R. (2018) · Cancer Medicine · doi:10.1002/cam4.1454 · Cited by 49
Precision Medicine in Hormone Receptor-Positive Breast Cancer
Nasrazadani, A., Thomas, R. A., Oesterreich, S., & Lee, A. V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00144 · Cited by 51
Shatsky, R. A., Parker, B. A., Bui, N. Q., Helsten, T. L., Schwab, R. B., Boles, S. G., & Kurzrock, R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1038 · Cited by 45
Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Woods, E., Le, D. T., Jakka, B. K., & Manne, A. (2022) · Cancers · doi:10.3390/cancers14092137 · Cited by 46
HER2-low gastric cancer: is the subgroup targetable?
Shimozaki, K., Fukuoka, S., Ooki, A., & Yamaguchi, K. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103679 · Cited by 46
Fabi, A., Malaguti, P., Vari, S., & Cognetti, F. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0380-5 · Cited by 43
Jackisch, C., Lammers, P. E., & Jacobs, I. A. (2017) · The Breast · doi:10.1016/j.breast.2017.01.010 · Cited by 47
Sudhan, D. R., Schwarz, L. J., Zotano, Á. G., Formisano, L., Nixon, M. J., Croessmann, S., Ericsson, P. I. G., Sanders, M. E., Balko, J. M., Avogadri-Connors, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1131 · Cited by 46
Cortés‐Hernández, L. E., Eslami‐S, Z., Pantel, K., & Alix‐Panabières, C. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.303586 · Cited by 47
Perrier, A., Boëlle, P., Chrétien, Y., Gligorov, J., Lotz, J., Brault, D., Compérat, É., Lefèvre, G., & Boissan, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227356 · Cited by 43
Aptamer-protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells
Xu, X. S., Li, L., Li, X., Tao, D., Zhang, P., & Gong, J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119963 · Cited by 43
A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer
Jørgensen, J. T., Winther, H., Askaa, J., Andresen, L., Olsen, D., & Mollerup, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.676939 · Cited by 43
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
Mazzotta, M., Krasniqi, E., Barchiesi, G., Pizzuti, L., Tomao, F., Barba, M., & Vici, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020254 · Cited by 43
Bozic, I., & Nowak, M. A. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042716-094839 · Cited by 41
Targeted therapies in gastric cancer and future perspectives
Yazıcı, O., Sendur, M. A. N., Ozdemir, N., & Aksoy, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.471 · Cited by 47
Costa, R. L. B., Carneiro, B. A., Wainwright, D. A., Santa-Maria, C. A., Kumthekar, P., Chae, Y. K., Gradishar, W. J., Cristofanilli, M., & Giles, F. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw532 · Cited by 44
Rüschoff, J., Lebeau, A., Kreipe, H. H., Sinn, H., Gerharz, C. D., Koch, W., Morris, S., Ammann, J. U., & Untch, M. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.164 · Cited by 42
Guo, Y., Zhao, Y., Wang, G., Chen, Y., Jiang, Y., Ouyang, L., & Liu, B. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.065 · Cited by 42
Su, L., Jiang, Y., Xu, Y., Li, X., Gao, W., Xu, C., Zeng, C., Song, J., Weng, W., & Liang, W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.063 · Cited by 43
Statler, A. B., Hobbs, B. P., Wei, W., Gupta, A., Blake, C. N., & Nahleh, Z. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-54402-9 · Cited by 42
Qiu, S., Chen, G., Peng, J., Liu, J., Chen, J., Wang, J., Li, L., & Yang, K. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12833 · Cited by 47
Primary and metastatic peritoneal surface malignancies
(2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00331-9 · Cited by 42
Review of the status of neoadjuvant therapy in HER2-positive breast cancer
Dowling, G. P., Keelan, S., Toomey, S., Daly, G. R., Hennessy, B. T., & Hill, A. D. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1066007 · Cited by 41
Swain, S. M., Schneeweiß, A., Gianni, L., Gao, J. J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M. S., Yoo, B., Cortés, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw695 · Cited by 41
Self-citationPotential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer
Wu, X., Shaikh, A. B., Yu, Y., Li, Y., Ni, S., Lü, A., & Zhang, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091851 · Cited by 45
Expression of miRNA‑206 and miRNA‑145 in breast cancer and correlation with prognosis
Quan, Y., Huang, X., & Quan, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.9440 · Cited by 48
Kennedy, S. P., Han, J. Z. R., Portman, N., Nobis, M., Hastings, J. F., Murphy, K. J., Latham, S. L., Cadell, A. L., Miladinovic, D., Marriott, G. R., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1127-y · Cited by 41
Cardiotoxicity of Contemporary Breast Cancer Treatments
Chuy, K. L., & Yu, A. F. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0646-1 · Cited by 42
Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore
Ayelet, A., & Ben‐Aharon, I. (2019) · Cancers · doi:10.3390/cancers11111669 · Cited by 51
Chen, S., Yu, L., Feng, Z., & Wang, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-6132-0 · Cited by 41
Kedashiro, S., Sugiura, A., Mizutani, K., & Takai, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-55460-9 · Cited by 44
Landscape of combination therapy trials in breast cancer brain metastasis
Fares, J., Kanojia, D., Rashidi, A., Ulasov, I. V., & Lesniak, M. S. (2020) · International Journal of Cancer · doi:10.1002/ijc.32937 · Cited by 44
Kim, J. S., & Kim, I. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936117 · Cited by 47
Balogun, T. A., Iqbal, M. N., Saibu, O. A., Akintubosun, M. O., Lateef, O. M., Nneka, U. C., Abdullateef, O. T., & Omoboyowa, D. A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1975570 · Cited by 56
Emerging Therapeutic Options for HER2-Positive Breast Cancer
Martín, M., & López‐Tarruella, S. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159167 · Cited by 41
Seung, B., Lim, H., Shin, J.-I., Kim, H.-W., Cho, S., Kim, S., & Sur, J. (2018) · Veterinary Pathology · doi:10.1177/0300985817750457 · Cited by 49
Self-citationvan Boxtel, W., Boon, E., Weijs, W. L. J., van den Hoogen, F. J. A., Flucke, U. E., & van Herpen, C. M. L. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.06.023 · Cited by 41
Li, Z., Song, Z., Hong, W., Yang, N., Wang, Y., Jian, H., Liang, Z., Hu, S., Peng, M., Yu, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01897-y · Cited by 48
Jiang, H., & Rugo, H. S. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015599389 · Cited by 43
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
Chan, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016656494 · Cited by 41
Lousberg, L., Collignon, J., & Jérusalem, G. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016665077 · Cited by 43
A Population-Based Analysis of Breast Cancer Incidence and Survival by Subtype in Ontario Women
Seung, S. J., Traore, A. N., Pourmirza, B., Fathers, K. E., Coombes, M., & Jerzak, K. J. (2020) · Current Oncology · doi:10.3747/co.27.5769 · Cited by 57
Chaudhary, S., Iniyan, A. M., Maurya, S. K., Nallasamy, P., Marimuthu, S., Shah, A., Atri, P., Ramakanth, C. V., Lele, S. M., Seshacharyulu, P., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01630-7 · Cited by 42
Clavarezza, M., Puntoni, M., Gennari, A., Paleari, L., Provinciali, N., D’Amico, M., & DeCensi, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1881 · Cited by 40
Smyth, L. M., Iyengar, N. M., Chen, M. F., Popper, S. M., Patil, S. N., Wasserheit-Lieblich, C., Argolo, D. F. S. D. T. E., Singh, J. C., Chandarlapaty, S., Sugarman, S. M., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3851-7 · Cited by 39
Self-citationCurrent Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research
Kawaguchi, T., Foster, B. A., Young, J. S., & Takabe, K. (2017) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-017-9378-7 · Cited by 40
Chotprakaikiat, W., Allen, A., Minh, D. B., Harden, E. L., Jobsri, J., Cavallo, F., Gleba, Y. Y., Stevenson, F. K., Ottensmeier, C. H. H., Klimyuk, V. I., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1166323 · Cited by 39
Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder
Tsuboi, M., Sakai, K., Maeda, S., CHAMBERS, J. K., Yonezawa, T., Matsuki, N., Uchida, K., & Nakayama, H. (2019) · Veterinary Pathology · doi:10.1177/0300985818817024 · Cited by 39
Clinical Development of the E75 Vaccine in Breast Cancer
Clifton, G. T., Gall, V., Peoples, G. E., & Mittendorf, E. A. (2016) · Breast Care · doi:10.1159/000446097 · Cited by 40
Survival of de novo stage IV breast cancer patients over three decades
Hölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Harbeck, N., Kiechle, M. B., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2306-1 · Cited by 38
Gamucci, T., Pizzuti, L., Natoli, C., Mentuccia, L., Sperduti, I., Barba, M., Sergi, D., Iezzi, L., Maugeri‐Saccà, M., Vaccaro, A., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1523095 · Cited by 39
Leech, A. O., Vellanki, S. H., Rutherford, E. J., Keogh, A., Jahns, H., Hudson, L., O’Donovan, N., Sabri, S., Abdulkarim, B., Sheehan, K. M., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1064-1 · Cited by 41
miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
Lindholm, E. M., Leivonen, S., Due, E. U., Nebdal, D. J. H., Git, A., Caldas, C., Børresen‐Dale, A., & Sahlberg, K. K. (2018) · MicroRNA · doi:10.2174/2211536608666181206124922 · Cited by 39
Kirschbrown, W. P., Wynne, C., Kågedal, M., Wada, R., Li, H., Wang, B., Nijem, I., Črnjević, T. B., Gasser, H., Heeson, S., et al. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1362 · Cited by 40
Self-citationGavilá, J., Oliveira, M., Pascual, T., Pérez-García, J. M., González, X., Canes, J., Paré, L., Calvo, I., Ciruelos, E., Muñoz-Mateu, M., et al. (2019) · BMC Medicine · doi:10.1186/s12916-018-1233-1 · Cited by 40
Self-citationDowling, G. P., Daly, G. R., Keelan, S., Boland, F., Toomey, S., Hill, A. D. K., & Hennessy, B. T. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.09.005 · Cited by 37
Emerging importance of HER3 in tumorigenesis and cancer therapy
Garrett, J. T., Tendler, S., Feroz, W., Kilroy, M. K., & Yu, H. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01008-y · Cited by 46
Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment
Liu, M., Li, Z., Yang, J., Jiang, Y., Chen, Z., Ali, Z., He, N., & Wang, Z. (2016) · Cell Proliferation · doi:10.1111/cpr.12266 · Cited by 42
Mukai, H., Saeki, T., Aogi, K., Naito, Y., Matsubara, N., Shigekawa, T., Ueda, S., Takashima, S., Hara, F., Yamashita, T., et al. (2016) · Cancer Science · doi:10.1111/cas.13017 · Cited by 37
Novel strategies to improve the endocrine therapy of breast cancer
Castrellon, A. B. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.323 · Cited by 40
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects
Brandão, M., Ponde, N. F., Poggio, F. B., Kotecki, N., Salis, M., Lambertini, M., & de Azambuja, E. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1477596 · Cited by 43
Press, M. F., Seoane, J. A., Curtis, C. N., Quinaux, E., Guzman, R., Sauter, G., EIERMANN, W., Mackey, J. R., Robert, N. J., Pieńkowski, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6012 · Cited by 37
Kim, T. Y., Han, H. S., Lee, K., Zang, D. Y., Rha, S. Y., Park, Y. I., Kim, J. S., Lee, K.-H., Park, S. H., Song, E., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00958-4 · Cited by 37
Swain, S. M., Tang, G., Lucas, P. C., Robidoux, A., Goerlitz, D. S., Harris, B. T., Bandos, H., Geyer, C. E., Rastogi, P., Mamounas, E. P., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05398-3 · Cited by 41
Self-citationAdvancements in Human Breast Cancer Targeted Therapy and Immunotherapy
Bou-Dargham, M. J., Draughon, S. A., Cantrell, V., Khamis, Z. I., & Sang, Q. A. (2021) · Journal of Cancer · doi:10.7150/jca.64205 · Cited by 37
Royce, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Chang, C. J. G., Ricks, T. K., Shetty, K. A., Kraft, J., Qiu, J., Song, P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3247 · Cited by 37
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
Saleh, K., Khoury, R., Khalife, N., Chahine, C., Ibrahim, R., Tikriti, Z., & Cesne, A. L. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.06 · Cited by 65
Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
Schlam, I. M., Loi, S., Salgado, R., & Swain, S. M. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104120 · Cited by 48
Self-citationSchneider, B. P., O’Neill, A., Shen, F., Sledge, G. W., Thor, A. D., Kahanic, S. P., Zander, P. J., & Davidson, N. E. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.405 · Cited by 36
Use of big data in drug development for precision medicine
Kim, R. S., Goossens, N., & Hoshida, Y. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1174062 · Cited by 41
Placido, S. D., Giuliano, M., Schettini, F., von Arx, C., Buono, G., Riccardi, F., Cianniello, D., Caputo, R., Puglisi, F., Bonotto, M., et al. (2018) · The Breast · doi:10.1016/j.breast.2017.12.012 · Cited by 36
Cancer Immunotherapy: The Dawn of Antibody Cocktails
Marrocco, I., Romaniello, D., & Yarden, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_2 · Cited by 39
Causal Bayesian gene networks associated with bone, brain and lung metastasis of breast cancer
Park, S. B., Hwang, K., Chung, C. K., Roy, D., & Yoo, C. (2020) · Clinical & Experimental Metastasis · doi:10.1007/s10585-020-10060-0 · Cited by 40
Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer
Yagisawa, M., Sawada, K., Nakamura, Y., Fujii, S., Yuki, S., Komatsu, Y., Yoshino, T., Sakamoto, N., & Taniguchi, H. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.11.002 · Cited by 35
Raguraman, P., Balachandran, A. A., Chen, S., Diermeier, S. D., & Veedu, R. N. (2021) · Cancers · doi:10.3390/cancers13215555 · Cited by 39
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017) · Cancers · doi:10.3390/cancers9040033 · Cited by 41
Diagnostic and Therapeutic Updates in Leptomeningeal Disease
Roy-O’Reilly, M. A., Lanman, T. A., Ruiz, A. N., Rogawski, D. S., Stocksdale, B. R., & Nagpal, S. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01432-2 · Cited by 38
Systemic Therapy in Breast Cancer
Corti, C., Batra-Sharma, H., Kelsten, M. F., Shatsky, R. A., Garrido-Castro, A. C., & Gradishar, W. J. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432442 · Cited by 42
The role of genomics and proteomics in drug discovery and its application in pharmacy
Dogiparthi, L. K., Bukke, S. P. N., Thalluri, C., Thalamanchi, B., Vidya, K. P., Sree, G. N., Tatiparthi, H., Uppicherla, D., & Thummaginjala, K. P. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-07155-2 · Cited by 38
Metronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the Literature
Banys-Paluchowski, M. J., Schütz, F., Ruckhäberle, E., Krawczyk, N., & Fehm, T. N. (2016) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0042-105871 · Cited by 37
Mohammadian, J., Sabzichi, M., Molavi, O., Shanehbandi, D., & Samadi, N. (2016) · PubMed Central · doi:10.22034/apjcp.2016.17.11.5031 · Cited by 39
Definitions and statistical properties of master protocols for personalized medicine in oncology
Renfro, L. A., & Mandrekar, S. J. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1372778 · Cited by 39
Rosemblit, C., Datta, J., Lowenfeld, L., Xu, S., Basu, A. B., Kodumudi, K. N., Wiener, D. A., & Czerniecki, B. J. (2018) · Oncotarget · doi:10.18632/oncotarget.25208 · Cited by 39
Ding, Y., Gong, C., Huang, D., Chen, R., Sui, P., Lin, K., Liang, G., Yuan, L., Xiang, H., Chen, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06651-x · Cited by 39
Lin, Y., Fu, F., Lv, J., Wang, M., Yan, L., Zhang, J., & Wang, C. (2020) · Medicine · doi:10.1097/md.0000000000018445 · Cited by 37
Li, Y., Qiu, Y., Li, H., Luo, T., Li, W., Wang, H., Shao, B., Wang, B., & Ge, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.664429 · Cited by 36
Masri, J. E., & Phadke, S. D. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000721 · Cited by 45
Miyashita, M., Gonda, K., Tada, H., Watanabe, M., Kitamura, N., Kamei, T., Sasano, H., Ishida, T., & Ohuchi, N. (2016) · Cancer Medicine · doi:10.1002/cam4.898 · Cited by 37
Double Agent: SPDEF Gene with Both Oncogenic and Tumor-Suppressor Functions in Breast Cancer
Ye, T., Feng, J. Y., Wan, X., Xie, D., & Liu, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s243748 · Cited by 46
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
Bartsch, R. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1792443 · Cited by 35
Jhaveri, K. L., Drago, J. Z., Shah, P. D., Wang, R., Pareja, F. G., Ratzon, F., Iasonos, A. E., Patil, S. N., Rosen, N. X., Fornier, M. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0047 · Cited by 35
Schlam, I. M., Church, S., HETHER, T. D., Chaldekas, K. M., Hudson, B. M., White, A. M., Maisonet, E., Harris, B. T., & Swain, S. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03113-9 · Cited by 40
Self-citation
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.